LentiGlobin Hogs The Limelight At CHMP’s First Amsterdam Meeting
Executive Summary
An opinion on whether bluebird bio’s transfusion-dependent β-thalassemia gene therapy, LentiGlobin, should be granted an EU marketing authorization is due this week as the EMA’s key scientific committee, the CHMP, meets for the first time in Amsterdam.
You may also be interested in...
EU Hat Trick For Bluebird’s Beta-Thalassemia Gene Therapy
bluebird bio is set to enter the EU market with the first gene therapy for transfusion-dependent β-thalassemia, after the European Medicines Agency reviewed its product in record time. Bluebird believes that the agency’s Priority Medicines (PRIME) and adaptive pathways programs have been instrumental in smoothing its path.
Goodbye To All That: EMA Leaves London After 24 years
March 1 saw the official departure of the European Medicines Agency for Amsterdam. The move from London, which is a result of the UK's decision to leave the EU, has caused huge upheaval for the agency, which has been in the UK capital since it was created in 1995.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.